Radiation Recall Dermatitis After Pre-Sensitization With Pegylated Liposomal Doxorubicin

Author： Gzell Cecelia   Carroll Susan   Suchowerska Natalka   Beith Jane   Tan King   Scolyer Richard  

Publisher： Informa Healthcare

ISSN： 0735-7907

Source： Cancer Investigation, Vol.27, Iss.4, 2009-05, pp. : 397-401

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II clinical trial with pegylated liposomal doxorubicin

By Poveda A.  

Sarcoma, Vol. 9, Iss. 3-4, 2005-09 ,pp. : 127-132

Informa Healthcare

Access to resources Recommend Favorite

Pemetrexed-associated radiation recall dermatitis

By Khanfir Kaouthar   Anchisi Sandro  

Acta Oncologica, Vol. 47, Iss. 8, 2008-01 ,pp. : 1607-1608

Informa Healthcare

Access to resources Recommend Favorite

Trabectedin plus pegylated liposomal doxorubicin: the return of a treatment option for ovarian cancer

By Clare John  

Future Oncology, Vol. 9, Iss. 12, 2013-12 ,pp. : 1-1

Future Medicine

Access to resources Recommend Favorite

Phase I Clinical Trial of Topotecan and Pegylated Liposomal Doxorubicin

By Garcia Agustin   Roman Lynda   Muderspach Laila   O'Meara Anne   Facio Grace   Edwards Susan   Burnett Alexander  

Cancer Investigation, Vol. 23, Iss. 8, 2005-11 ,pp. : 665-670

Informa Healthcare

Access to resources Recommend Favorite

Efficacy of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma

By Lind Pehr   Naucler Gisela   Holm Agneta   Gubanski Michael   Svensson Christer  

Acta Oncologica, Vol. 46, Iss. 2, 2007-01 ,pp. : 230-233

Informa Healthcare

Access to resources Recommend Favorite